Skin Barrier FunctionSkin Barrier Function
有病率: Impaired in multiple conditions: eczema, psoriasis, rosacea, aged skin, sensitive skin
Evidence-Ranked Ingredients
| 成分 | グレード | 研究数 | 効果の方向 | |
|---|---|---|---|---|
| Ceramides | C | 5 | Positive | 詳細を見る → |
| Hyaluronic Acid | D | 3 | Positive | 詳細を見る → |
| Bifidobacterium lactis | D | 2 | Positive | 詳細を見る → |
About
The stratum corneum is organised as bricks and mortar. Corneocytes are the bricks; the mortar is a lipid bilayer of roughly 50 percent ceramides, 25 percent cholesterol and 15 percent free fatty acids. That composition is not incidental, and the proportions matter more than the absolute quantity, which is why a barrier can fail while total lipid content looks adequate. Three ingredients carry an evidence grade against barrier function here, one at Grade C and two at Grade D, across 10 studies and 560 participants, the thinnest graded set on this site apart from the single-ingredient conditions.
A compromised barrier is a shared upstream feature rather than a disease in itself. It underlies eczema, contributes to psoriasis and rosacea, accompanies intrinsic aging, and defines what is colloquially called sensitive skin. The measurable consequence is elevated transepidermal water loss, and the experienced ones are stinging with products, redness, flaking and greater susceptibility to infection. Filaggrin mutations, over-washing with harsh cleansers, low humidity, topical retinoid use and deficiency of essential fatty acids each degrade it by a different route.
Ceramides hold the highest rating in the set at Grade C on 5 studies and 280 participants. Supplying orally the exact lipid class the barrier lacks is mechanistically appealing and practically indirect, since ingested sphingolipids are hydrolysed and must be resynthesised by keratinocytes rather than deposited intact. Trials generally use plant-derived glucosylceramides and measure transepidermal water loss and corneometry, which are at least the correct endpoints.
Hyaluronic acid and Bifidobacterium lactis sit at Grade D on 3 studies and 180 participants and 2 studies and 100 participants respectively. The probiotic rationale runs through the gut-skin axis, where changes in intestinal barrier integrity and systemic inflammatory tone are proposed to alter cutaneous barrier recovery, a chain with more links than the evidence currently supports. A systematic review and meta-analysis of dietary supplementation for skin moisturizing in healthy adults offers the most relevant pooled estimate for this endpoint [1], and reviews of nutrition in atopic dermatitis cover the same barrier biology in its best-studied disease context [2].
The interpretive risk on this page is proxy substitution. Barrier function is measured instrumentally, and a statistically significant reduction in transepidermal water loss can be too small to alter how skin behaves. With 10 studies and 560 participants total, the honest summary is that oral support for barrier repair remains an early hypothesis rather than a demonstrated one.
Topical measures have the stronger evidence base for this specific endpoint, principally reduced washing frequency, non-stripping cleansers and lipid-replenishing emollients applied to damp skin. Barrier dysfunction that persists despite those measures, or that appears abruptly, is better investigated than supplemented.
Common Symptoms
Risk Factors
- Filaggrin gene mutations
- Aging
- Over-washing with harsh cleansers
- Low humidity
- Nutritional deficiencies (essential fatty acids, ceramides)
- Topical retinoid use
- Atopic predisposition
Frequently Asked Questions
What supplements are studied for Skin Barrier Function?
How is the evidence for Skin Barrier Function supplements graded?
How many studies on Skin Barrier Function supplements have been reviewed?
What are common symptoms of Skin Barrier Function?
References
- 1. Effectiveness of Dietary Supplement for Skin Moisturizing in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. — Frontiers in nutrition, 2022 PMID 35719159
- 2. Nutrition and Atopic Dermatitis. — Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2021 PMID 33692290
Related Conditions
共通の研究済み成分を持つ症状
FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。